Abstract-We examined the utility of coronary artery calcium (CAC) for cardiovascular risk stratification among hypertensive adults, including those fitting eligibility for SPRINT (Systolic Blood Pressure Intervention Trial). Additionally, we used CAC to identify hypertensive adults with cardiovascular disease (CVD) mortality rates equivalent to those observed in SPRINT who may, therefore, benefit from the most intensive blood pressure therapy. Our study population included 16 167 hypertensive patients from the CAC Consortium, among whom 6375 constituted a "SPRINT-like" population.
levated blood pressure (BP) is a major risk factor for cardiovascular events. 1 According to the 2017 American College of Cardiology/American Heart Association (ACC/ AHA) guidelines, hypertension is currently defined as BP ≥130/80 mm Hg. 2 Based on the new definition, the crude prevalence of hypertension in US adults is 45.6%, which is a substantial 13.7% absolute increase from the prevalence based on the prior definition of hypertension. 3, 4 Although treating hypertension has been shown to decrease cardiovascular events, there remains considerable debate on the optimal BP targets in patients with hypertension. The landmark 2015 SPRINT (Systolic Blood Pressure Intervention Trial) reported a 25% reduction in the primary composite cardiovascular outcome and a 27% reduction in allcause mortality among hypertensive nondiabetic individuals aged >50 years at high cardiovascular risk who were treated intensively to the systolic BP target ≤120 mm Hg. 5 However, findings from SPRINT seem to differ from results from the HOPE-3 trial (Heart Outcomes Prevention Evaluation-3), which showed no statistical benefit of additional BP lowering among intermediate cardiovascular risk adults. 6 Although various differences may contribute to the disparate findings, a primary difference in the studies was the baseline risk of the population. [7] [8] [9] For instance, the population enrolled in SPRINT had more than twice the risk of cardiovascular disease (CVD) compared with that enrolled in HOPE-3 (annual CVD event rate: 2.2% versus 0.8%). Based in part on these data, the new guidelines-for the first time ever in the United States-incorporated the use of risk scoring to guide hypertension therapy in stage 1 hypertension (systolic BP: 130-139 mm Hg or diastolic BP: 80-89 mm Hg), although advanced risk stratification tools were not specifically recommended. 2 Coronary artery calcium (CAC) detected by noncontrast cardiac computerized tomography (CT) estimates the burden of coronary atherosclerosis and is a strong independent predictor of future cardiovascular events. CAC=0 is associated with low event rates and all-cause mortality, 10, 11 whereas an increasing CAC score is associated with a high risk of cardiovascular events. [12] [13] [14] Additionally, CAC improves risk reclassification for cardiovascular events beyond traditional risk factors. 15 There is an increasing interest in using CAC scoring to risk-stratify hypertensives for selecting personalized BP goals; for example, a combined CVD risk-CAC approach has been shown to identify individuals who might benefit from more or less aggressive antihypertensive therapy. 16 Therefore, in this study, we aimed to quantify the ability of CAC to further stratify cardiovascular risk in patients with hypertension. Additionally, we assessed if CAC scoring could be used to identify hypertensive individuals aged >50 years who, by virtue of their CAC scores, have observed event rates similar to those enrolled in the SPRINT trial. We hypothesized that CAC may identify such patients that could potentially benefit from intensive BP therapy, consistent with the guidelines emphasis on a risk-based approach.
Methods
Data and study materials are available from the corresponding author on reasonable request.
Study Design and Study Population
The CAC Consortium is a multicenter, retrospective cohort of 66 636 participants, aimed at examining the association between clinical CAC scoring and long-term cause-specific mortality. The methods and baseline results of the cohort have been described previously. 17 Briefly, 4 high-volume centers contributed detailed patient information, including demographics, risk factor data, and CAC score results, to a centralized coordinating center. All patients in the cohort were free of clinical CVD at baseline and were clinically referred for CAC-based risk stratification. Patients were enrolled between 1991 and 2010 and follow-up was data collected through 2014. Comparison of the CAC Consortium with the contemporary National Health and Nutrition Examination Survey 2001 to 2002, MESA (Multi-Ethnic Study of Atherosclerosis), and Framingham Offspring/ third Generation cohorts have been previously published. 17 Consent for participation in research was collected at the centers at the time of CAC scanning, and Institutional Review Board approval for coordinating center activities was obtained at the Johns Hopkins Hospital.
The primary population for this study includes CAC Consortium participants with baseline hypertension. Thus, 16 167 participants were included for the primary analysis. A secondary analysis was also conducted using participants who were hypertensive, were >50 years of age, and had Framingham risk score >15%. This subpopulation, which was similar to the standard-treatment arm of SPRINT, was defined as the SPRINT-like population and included 6375 individuals.
CAC Scoring
Noncontrast, cardiac-gated CT scans were performed for CAC scoring at each individual site using a common protocol for each CT scanner technology. The Agatston method was used to quantify CAC for all patients. Approximately, 93% of the scans were performed by electron beam tomography, whereas 7% of the scans were obtained by multidetector CT. Prior studies revealed no meaningful clinical differences between CAC scores derived from electron beam tomography versus multidetector CT scanners. 18 For this analysis, patients were categorized into 4 CAC score groups-CAC=0, CAC 1 to 99, CAC 100 to 399, and CAC ≥400.
Outcome Ascertainment-Cause-Specific Mortality
The primary outcomes for the study were coronary heart disease (CHD) and CVD mortality assessed over mean 11.6±3.6 years of follow-up. Mortality was accessed by linking patient records with the Social Security Administration Death Master File using a previously validated algorithm. Death certificates were obtained from the National Death Index, and underlying cause of death was categorized into common causes of death using International Classification of Diseases, Ninth Revision and International Classification of Diseases, Tenth Revision codes as previously described. 17 Internal validation studies for the CAC Consortium against known deaths identified via the electronic medical record revealed sensitivity ranging from 72% to 90% for identifying known deaths, with >90% specificity. Detailed comparison of death rates in the CAC Consortium with the US Census and MESA has been previously published.
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Risk Factor Definitions
Definitions of traditional risk factors have been described previously. 17 Hypertension was defined as a prior diagnosis of hypertension or use of antihypertensive medications. This was based on the old definition of hypertension, before the 2017 ACC/AHA guideline (systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg). Similarly, diabetes mellitus was defined as prior diagnosis of diabetes mellitus or treatment with oral hypoglycemic drugs or insulin. Dyslipidemia was defined as prior diagnosis of primary hyperlipidemia (LDL-C [low-density lipoprotein cholesterol] >160 mg/dL), prior diagnosis of dyslipidemia (elevated triglycerides >150 mg/dL and/or low HDL-C [high-density lipoprotein cholesterol] <40 mg/dL in men and <50 mg/dL in women), or treatment with any lipid-lowering drug. Current smoking was categorized as a binary variable (considered present/absent). Family history of CHD was generally defined as the presence of a first degree relative with a history of CHD, although 1 site (with 11% of patients) used a definition of premature family history (<55 years old in a male relative and <65 years old in a female relative). The 10-year atherosclerotic CVD (ASCVD) risk score was calculated using the Pooled Cohort Equations. 19 Simple rule-based imputation method was used in the event of missing continuous data for BP and lipid measurements for the calculation of the ASCVD risk score.
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Statistical Analysis
Baseline characteristics of the study population were compared across the 4 CAC score categories. For categorical variables, proportions were calculated, and for continuous variables, mean±SD or median±IQR were calculated based on the normality of the data. For formal comparisons, χ 2 test and ANOVA or Kruskal-Wallis testing were used as appropriate.
Absolute CHD and CVD mortality rates were calculated by dividing the total number of deaths by the total number of patient-years of follow-up and then reported per 1000 patient-years.
To evaluate the association of CAC score with CHD and CVD mortality, survival analyses were conducted using individual subject time-to CHD-or CVD-mortality data. After graphical confirmation of the proportional hazards assumption, hazard ratios (HRs) and 95% CIs were calculated using the Cox proportional hazards regression model with CAC=0 as the reference group, adjusting for age and sex (model 1) and further adjusting for hyperlipidemia, smoking status, family history of CHD, and diabetes mellitus (model 2). The regression analysis was also repeated: (1) after stratifying by 10-year ASCVD risk groups (<10%, ≥10%); (2) within the dedicated SPRINT-like population (age >50 years and Framingham risk score >15%); (3) after excluding participants with diabetes mellitus in the SPRINT-like population; and (4) among the study population not eligible for SPRINT (age <50 years or age ≥50 years and Framingham risk score <15%). The ASCVD 10% cut point was based on the new ACC/AHA hypertension guidelines recommendations for risk stratification of the stage 1 hypertension group.
We performed a separate analysis to further compare CHD-and CVD-mortality risk across different CAC and ASCVD risk groups using Cox proportional hazards model with CAC=0 and ASCVD <10% as the reference group. HR estimates in this analysis were adjusted for age, sex, hyperlipidemia, smoking status, family history of CHD, and diabetes mellitus (model 2). Although hazards are compared across CAC/ASCVD groups, formal statistical reclassification analysis (ie, net reclassification improvement) was not performed in this study because of the different outcomes studied (ASCVD versus CHD/CVD mortality in the CAC Consortium).
An additional analysis was conducted among hypertensive participants aged >50 years to determine what CAC scores would translate into CVD death rates equivalent to those observed in the standardtreatment group of the SPRINT trial (0.43%/y). To accomplish this, CVD mortality rates observed in SPRINT were first age-standardized to the population structure of the CAC Consortium (age-standardized annual CVD mortality rate=0.35%/y). Then, using a plot of CAC score (x axis) versus annual CVD mortality rates (y axis), a y-axis line was placed at the annual CVD mortality rate observed in SPRINT, and its intersection with the CAC-CVD mortality plot was interpreted as the CAC-score equivalent of SPRINT-level risk (ie, the CAC score that would produce risk equivalent to the standard-treatment arm of the SPRINT trial). A confidence band was applied to reflect the possible 15% underestimation of risk within the CAC Consortium. All analyses were performed using Stata 13.0 (StataCorp, College Station, TX), and a 2-tailed P<0.05 was considered to be significant.
Results
The baseline characteristics of the 16 167 participants are shown in Table 1 . The mean age was 58.1±10.6, with 35.8% women and 85.8% whites. About 32% participants had CAC=0, and 36.2% participants had CAC ≥100. The mean 10-year ASCVD risk score was 12.1%. Participants with higher CAC scores had an increased burden of ASCVD risk factors. For instance, those with CAC >100 were more likely to be older, have hyperlipidemia and diabetes mellitus, and were more likely to be current smokers compared with those with CAC<100.
A total of 6375 (39.4%) participants qualified for the SPRINT-like subpopulation (age >50 years and Framingham risk score >15%). The mean age in this subpopulation was 63 years, and there were 75.1% males and 86.5% whites. Additionally, 17.7% participants had CAC=0, and 51.5% participants had CAC ≥100.
Over the mean follow-up of 11.6±3.6 years, there were 409 CVD deaths and 207 CHD deaths in the total study population. The overall mortality rate in the study population by the CAC categories CAC=0, 1 to 99, >100, and 100 to 399 were 0.3, 0.5, 1.3, 4.1 per 1000 person-years for CHD, and 0.8, 1.4, 2.9, 6.9 per 1000 person-years for CVD, respectively. Figure 1 shows the CHD and CVD mortality rates per 1000 person-years by increasing CAC scores stratified by ASCVD risk groups (<10% versus ≥10%). In each risk group, mortality rates increased with increasing CAC scores. For instance, CVD mortality among individuals with CAC ≥400 was twice that of CAC 100 to 399 among the ASCVD ≥10% group (8.15 versus 4.24 per 1000 person-years). Notably, mortality rates at higher CAC scores (≥400) in ASCVD <10% was greater than mortality rates of lower CAC scores (CAC 1-99) in the ASCVD ≥10% group. This pattern was more pronounced for CHD compared with CVD. Table 2 shows the multivariable-adjusted HRs and 95% CIs for CHD and CVD deaths across increasing CAC score categories in the total study population. Increased CAC scores were associated with increased risk of CHD and CVD deaths, most notably among the CAC100-399 and CAC ≥400 categories. In the fully adjusted model, individuals with CAC ≥400 had ≈4× and 3.5× increased risk of experiencing a CHD and CVD death, respectively, compared with those with CAC=0. Table 3 demonstrates the multivariable-adjusted HRs (95% CIs) for CHD and CVD deaths by CAC score categories stratified by the ASCVD risk groups (<10%, ≥10%). A similar Continuous variables shown as mean±SD, categorical variables shown as n (%). ASCVD indicates atherosclerotic cardiovascular disease; CAC, coronary artery calcium; and CHD, coronary heart disease.
*P value was calculated for continuous variables using a nonparametric test for trend and for categorical variables using the χ 2 test.
pattern was observed in this analysis-higher CAC score categories were positively associated with risk for both CHD and CVD deaths in both risk groups. Higher CAC score groups, such as CAC 100 to 399 and ≥400, had higher HRs (versus CAC=0) in the ASCVD <10% group compared with lower CAC score groups, such as 1 to 99, in the ASCVD ≥10% group. Similarly, when CAC=0 and ASCVD <10% was used as a common reference group, the higher CAC score groups in the ASCVD <10% (for instance, CAC 100 to 399) group had higher HRs compared with the lower CAC score groups (CAC 1 to 99) in the ASCVD ≥10% group (Table S1 in the onlineonly Data Supplement). Increasing CAC score was also similarly positively associated with increased risk of both CHD and CVD deaths in the SPRINT-like population (Table 4) , after the exclusion of participants with diabetes mellitus in the SPRINT-like population (Table S2) , and among the study population not eligible for SPRINT (Table S3) . Figure 2 shows the graphical calculation of the CAC score threshold associated with SPRINT-level risk. A CAC score in the range of 165 to 270 was associated with the age-adjusted annual CVD mortality rate observed in the SPRINT trial (0.35% per year). A score in this range is thus associated with CVD mortality rates equivalent to the observed mortality rate in the standard therapy arm of SPRINT.
Discussion
In our study of a large, clinical cohort of asymptomatic patients with hypertension free of baseline CVD, increasing CAC scores were strongly associated with CHD and CVD death rates after adjustment for traditional cardiovascular risk factors. Additionally, CAC stratified risk of CVD and CHD deaths across guideline-based ASCVD risk categories, resulting in recategorization of risk across the 10% ASCVD risk threshold. CAC stratified risk similarly well in a subgroup of patients who would be eligible for the SPRINT trial. Additionally, our modeling suggests that hypertensive persons aged >50 years with a CAC score near 220 (estimated range, 165 to 270) have equivalent risk to the SPRINT trial population and, therefore, may be candidates for the most aggressive BP goals.
There are a limited number of studies on the predictive ability of CAC among those with hypertension. Our results add to the growing evidence of the predictive value of CAC scoring on CHD and CVD outcomes among hypertensives. For example, our findings were similar to those reported by McEvoy et al, 16 who showed, among 3733 hypertensive participants of mean age 65 years from the MESA, a similarly increased hazard for incident all-cause CVD events and heart failure with higher CAC scores (CAC 1 to 99 and CAC >100) compared with CAC=0, specifically among those with systolic BP in the range of 120 to 159 mm Hg. Similarly, Erbel et al, 20 in 2012, evaluated the predictive ability of CAC in different stages of hypertension among 4181 participants from the Heinz Nixdorf Recall study. Consistent with our findings, the authors showed increasing CAC scores were associated with increased primary and secondary endpoints in all stages of hypertension. However, point estimates reported were larger compared with our estimates, which is likely explained by the authors' choice of a reference group of normotensives with CAC=0, compared with our reference group of hypertensives with CAC=0.
There has been an increasing interest in the use of cardiovascular risk assessment to help define individual BP treatment goals. The new ACC/AHA guidelines have focused on the ASCVD 10% cut point to guide antihypertensive treatment. 2 In our analysis, we demonstrate that CAC can recategorize risk around the 10% threshold; CAC >100 identified individuals in the low-risk group (ASCVD <10%) having higher risk of CVD and CHD death compared with those with lower CAC scores in the higher risk group (ASCVD ≥10%). In line with our findings, McEvoy et al 16 have previously demonstrated, among individuals with hypertension, a higher HR for higher CAC scores (CAC >100 versus CAC=0) in ASCVD <15% group compared with the lower HR for lower CAC scores in the ASCVD >15% group.
Besides recommending a risk-based approach to hypertension therapy, the 2017 ACC/AHA guidelines also propose more intensive BP targets compared with previous guidelines. A major influence for this was the SPRINT trial. In our study, we demonstrated that CAC can identify people with risk equivalent to the SPRINT study. This has clinical implications for identifying candidates with advanced subclinical atherosclerosis who may be more likely to benefit from the most from aggressive BP lowering. Hypertensive individuals with a CAC score of approximately ≥220 (range, 165-270) and aged >50 years would have event rates similar to that of SPRINT and may, therefore, benefit from intensive BP therapy. Our results thus strengthen the evidence for a combined CAC/ASCVD-risk approach that can help identify individuals at the greatest risk who could benefit from an aggressive BP therapy. Strengths of our study include using one of the largest study populations with hypertension, a long follow-up, and ascertainment of cause-specific mortality (CHD and CVD deaths). To our knowledge, this is also the first CAC-based analysis using the ASCVD 10% cut point of the 2017 ACC/ AHA guidelines. Additionally, we have also modeled CAC for the first time in the context of the SPRINT trial results, using an innovative approach for identifying a threshold of CAC score that would identify SPRINT-level risk.
Our study also has some limitations. Hypertension and other risk factors were predominantly obtained by self-report or prior treatment which could potentially introduce recall bias. However, self-reporting of hypertension and other risk factors has been validated to assess risk factor data of participants. 21 Additionally, study participants-who were free of baseline CVD-were clinically referred to the centers for CAC scoring for risk stratification which could potentially limit generalizability to the overall healthy population. We also did not possess other measurements that were used by the SPRINT trial to determine trial eligibility, such as the presence of chronic kidney disease.
In conclusion, we demonstrated that (1) CAC risk stratifies hypertensives, including those who are SPRINT eligible; (2) CAC recategorizes risk around the ASCVD 10% threshold; (3) A CAC score of around 220 can identify hypertensives with risk equivalent to the SPRINT study. This score threshold can, therefore, help identify candidates for the most aggressive BP lowering
Perspectives
This study greatly strengthens the evidence of CAC scoring as an advanced risk stratification tool among adults with hypertension and demonstrates the utility of CAC to inform making more personalized BP goals. The findings support stronger endorsement of the use of CAC scoring in future guidelines.
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